E-7766 is under clinical development by Eisai and currently in Phase I for Lymphoma. According to GlobalData, Phase I drugs for Lymphoma have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how E-7766’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
E-7766 is under development for the treatment of solid tumors including head and neck squamous cell carcinoma (HNSCC), breast cancer, colorectal cancer, melanoma and lymphoma. The drug candidate acts by targeting the stimulator of interferon gene protein (STING). It is administered through intravesical and intratumoral routes.It was also under development for treatment of non-muscle invasive bladder cancer.
Eisai is a pharmaceutical company that discovers, develops, manufactures and markets pharmaceuticals, including prescription medicines, OTC drugs and generics. The company’s franchise areas in research include neurology and oncology. Eisai’s major products include Pariet/AcipHex, a proton pump inhibitor; Aricept, an anti-Alzheimer agent; perampanel, Halaven, an anti-cancer agent; Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has production plants in Japan, the UK, China and India and laboratories in Japan, the US and the UK; operations in the Americas, Asia and Latin America, EMEA and Oceania with overseas sales offices in the US, Germany, France, China and South Korea. Eisai is headquartered in Tokyo, Japan.
For a complete picture of E-7766’s drug-specific PTSR and LoA scores, buy the report here.